Teacher Retirement System of Texas Has $386,000 Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Teacher Retirement System of Texas raised its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 21.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 16,385 shares of the company’s stock after purchasing an additional 2,883 shares during the quarter. Teacher Retirement System of Texas’ holdings in Dyne Therapeutics were worth $386,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Quantbot Technologies LP acquired a new stake in Dyne Therapeutics in the 3rd quarter valued at $34,000. Point72 DIFC Ltd acquired a new stake in shares of Dyne Therapeutics in the 3rd quarter valued at $36,000. KBC Group NV grew its holdings in shares of Dyne Therapeutics by 45.3% in the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after purchasing an additional 978 shares during the last quarter. E Fund Management Co. Ltd. increased its position in shares of Dyne Therapeutics by 11.8% during the 4th quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company’s stock worth $279,000 after purchasing an additional 1,249 shares in the last quarter. Finally, Legato Capital Management LLC bought a new position in Dyne Therapeutics during the 4th quarter valued at about $305,000. 96.68% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

DYN has been the topic of several research analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $45.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. Scotiabank assumed coverage on Dyne Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price target for the company. Guggenheim restated a “buy” rating on shares of Dyne Therapeutics in a report on Friday, January 24th. Chardan Capital restated a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 17th. Finally, Robert W. Baird began coverage on shares of Dyne Therapeutics in a research report on Friday, December 13th. They set an “outperform” rating and a $46.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $47.46.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN opened at $10.46 on Tuesday. The company’s 50 day simple moving average is $13.20 and its 200 day simple moving average is $23.23. Dyne Therapeutics, Inc. has a fifty-two week low of $9.96 and a fifty-two week high of $47.45. The firm has a market capitalization of $1.18 billion, a P/E ratio of -2.94 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.04. Sell-side analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the sale, the insider now owns 199,087 shares of the company’s stock, valued at approximately $2,777,263.65. This trade represents a 1.29 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Over the last quarter, insiders have sold 6,237 shares of company stock worth $77,760. Insiders own 20.77% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.